360ip’s partner technology uses a c143 monoclonal antibody for detecting a bovine individual which has a possibility of onset of bovine leukemia. The technology is safe, cost effective and accurate. The partner’s method for the detection and prediction of the onset of bovine leukemia has the following advantages:
May be applied to a wide variety of cattle.
Conveniently, rapidly and accurately determines the onset of BLV for a large number of bovine individuals.
Diagnosis of active BLV and predicting resistance/susceptibility to BLV can be achieved all in one sample.
Can be performed using any of the fluorescent antibody methods, flow cytometry, ELISA, immune-histological assay and PCR.
Can measure increases in viral levels in addition to a yes/no determination.
Can be provided in a freeze-dried form or in a liquid form.